Zacks Investment Research lowered shares of Celcuity (NASDAQ:CELC) from a strong-buy rating to a hold rating in a report issued on Tuesday, Zacks.com reports.

According to Zacks, “Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular activity driving a patient’s cancer and the targeted therapy. Celcuity Inc. is based in Minneapolis, United States. “

A number of other brokerages also recently commented on CELC. HC Wainwright set a $31.00 price objective on Kura Oncology and gave the stock a buy rating in a research report on Wednesday, May 8th. ValuEngine downgraded Valero Energy from a hold rating to a sell rating in a research report on Wednesday, May 8th.

NASDAQ CELC opened at $23.39 on Tuesday. The stock has a market capitalization of $236.85 million, a P/E ratio of -31.61 and a beta of 0.57. The firm has a 50 day moving average price of $22.05. Celcuity has a 1-year low of $18.31 and a 1-year high of $31.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 26.94 and a current ratio of 26.94.

Celcuity (NASDAQ:CELC) last released its earnings results on Tuesday, May 7th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.04. Research analysts forecast that Celcuity will post -0.81 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the stock. Northern Trust Corp lifted its position in Celcuity by 2.0% during the fourth quarter. Northern Trust Corp now owns 61,888 shares of the company’s stock worth $1,484,000 after buying an additional 1,223 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in Celcuity by 13,655.6% during the first quarter. BNP Paribas Arbitrage SA now owns 1,238 shares of the company’s stock worth $27,000 after buying an additional 1,229 shares in the last quarter. Kessler Investment Group LLC lifted its position in Celcuity by 46.3% during the first quarter. Kessler Investment Group LLC now owns 7,017 shares of the company’s stock worth $154,000 after buying an additional 2,222 shares in the last quarter. Geode Capital Management LLC lifted its position in Celcuity by 9.1% during the fourth quarter. Geode Capital Management LLC now owns 35,035 shares of the company’s stock worth $840,000 after buying an additional 2,930 shares in the last quarter. Finally, Nelson Roberts Investment Advisors LLC purchased a new position in Celcuity during the first quarter worth approximately $115,000. Hedge funds and other institutional investors own 22.05% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.

See Also: Rule of 72

Get a free copy of the Zacks research report on Celcuity (CELC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.